Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) Non Operating Income (2020 - 2025)

Apellis Pharmaceuticals (APLS) has 6 years of Non Operating Income data on record, last reported at -$151000.0 in Q4 2025.

  • For Q4 2025, Non Operating Income rose 91.44% year-over-year to -$151000.0; the TTM value through Dec 2025 reached -$133000.0, up 93.87%, while the annual FY2025 figure was -$133000.0, 93.87% up from the prior year.
  • Non Operating Income reached -$151000.0 in Q4 2025 per APLS's latest filing, down from $37000.0 in the prior quarter.
  • Across five years, Non Operating Income topped out at $50.3 million in Q4 2022 and bottomed at -$1.8 million in Q4 2024.
  • Average Non Operating Income over 5 years is $2.4 million, with a median of -$32500.0 recorded in 2021.
  • Peak YoY movement for Non Operating Income: tumbled 1320.0% in 2021, then skyrocketed 1256625.0% in 2022.
  • A 5-year view of Non Operating Income shows it stood at -$4000.0 in 2021, then surged by 1256625.0% to $50.3 million in 2022, then plummeted by 99.56% to $219000.0 in 2023, then plummeted by 905.94% to -$1.8 million in 2024, then surged by 91.44% to -$151000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Non Operating Income were -$151000.0 in Q4 2025, $37000.0 in Q3 2025, and $146000.0 in Q2 2025.